Tisagenlecleucel, the only commercially available CD19-directed CAR-T cell therapy for paediatric patients with BCP-ALL, is approved by the US Food and Drug Administration and European Medicines Agency for the indication of a second or higher relapse, a relapse post HSCT, or refractory disease at primary diagnosis or relapse. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.